HUTCHMED Shares Surge 17% on $1.3B Cancer Drug Deal with GSK

Key Facts

1HUTCHMED entered a licensing agreement with GSK for an experimental cancer therapy worth up to $1.295 billion.

2GSK will receive exclusive rights to develop and commercialize HMPL-A830 outside Mainland China, Hong Kong, Macau, and Taiwan.

3HUTCHMED shares jumped 17% to 210p on the London Stock Exchange following the deal announcement.

In a move reflecting the growing value of specialized biotech pipelines, HUTCHMED has entered into a major licensing agreement with GSK for an experimental cancer therapy worth up to $1.295 billion. Under the terms, GSK will receive exclusive rights to develop and commercialize the HMPL-A830 therapy outside of Mainland China, Hong Kong, Macau, and Taiwan. Following the announcement, HUTCHMED shares surged 17% to reach 210p on the London Stock Exchange.

This partnership provides HUTCHMED with significant capital and a tier-1 pharmaceutical partner for its oncology pipeline, while GSK expands its portfolio in colorectal, pancreatic, and lung cancer treatments. Per market data, the double-digit jump in share price underscores investor confidence in the potential milestone payments and royalties. The deal marks a significant step for HUTCHMED's proprietary platform in the global market.

Looking ahead, a global Phase I clinical program is expected to commence in the second half of 2026, with HUTCHMED leading the initial development before GSK assumes global responsibility. As of September 3, 2026, with specific current price data unavailable, market participants are monitoring the stock's ability to maintain its recent gains. Key upcoming catalysts for broader market sentiment include US jobless claims and inflation data from the Eurozone.